Improvement of the rett syndrome phenotype in a mecp2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor

Neuropsychopharmacology

Volumn 39, Issue 12, 2014, Pages 2846-2856

  Szczesna, Karolina ^a   De La Caridad, Olga ^a   Petazzi, Paolo ^a   Soler, Marta ^a   Roa, Laura ^a   Saez, Mauricio A ^a   Fourcade, Stéphane ^a,b,c   Pujol, Aurora ^a,b,c,d   Artuch Iriberri, Rafael ^c,e   Molero Luis, Marta ^c,e   Vidal, August ^f   Huertas, Dori ^a   Esteller, Manel ^a,b,d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e HOSPITAL SANT JOAN DE DÉU   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; MECP2 PROTEIN, MOUSE; METHYL CPG BINDING PROTEIN 2;

ANIMAL; BODY WEIGHT; BRAIN; BREATHING; C57BL MOUSE; CELL ENLARGEMENT; DEFICIENCY; DENDRITE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MOVEMENT (PHYSIOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; RETT SYNDROME;

ANIMALS; ANTI-DYSKINESIA AGENTS; AROMATIC AMINO ACID DECARBOXYLASE INHIBITORS; BODY WEIGHT; BRAIN; CELL ENLARGEMENT; DENDRITES; DISEASE MODELS, ANIMAL; DOPA DECARBOXYLASE; DOPAMINERGIC NEURONS; LEVODOPA; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE, INBRED C57BL; MICE, KNOCKOUT; MOVEMENT; PHENOTYPE; RESPIRATION; RETT SYNDROME;

EID: 84936761220     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.136     Document Type: Article

References (55)

1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185-188.
2. Armstrong D, Dunn JK, Antalffy B, Trivedi R (1995). Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 54:195-201.
3. Armstrong D (1995). The neuropathology of Rett syndrome-overview 1994. Neuropediatrics 26:100-104.
4. Bauman ML, Kemper TL, Arin DM (1995). Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology 45:1581-1586.
5. Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, Waltersm J et al (1997). Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 17:6761-6768.
6. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88.
7. Brautigam C, Steenbergen-Spanjers GC, Hoffmann GF, Dionisi-Vici C, van den Heuvel LP, Smeitink JA et al (1999). Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 45:2073-2078.
8. Chahrour M, Zoghbi HY (2007). The story of Rett syndrome: from clinic to neurobiology. Neuron 56:422-437.
9. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R (2006). The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49:341-348.
10. Chao HT, Zoghbi HY, Rosenmund C (2007). MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56:58-65.
11. Chapleau CA, Boggio EM, Calfa G, Percy AK, Giustetto M, Pozzo-Miller L (2012). Hippocampal CA1 pyramidal neurons of Mecp2 mutant mice show a dendritic spine phenotype only in the presymptomatic stage. Neural Plast, published online 30 July 2012, doi:10.1155/2012/976164.
12. Chapleau CA, Calfa GD, Lane MC, Albertson AJ, Larimore JL, Kudo S et al (2009). Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol Dis 35:219-233.
13. Chartoff EH, Marck BT, Matsumoto AM, Dorsa DM, Palmiter RD (2001). Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci USA 98:10451-10456.
14. Chiron C, Bulteau C, Loc'h C, Raynaud C, Garreau B, Syrota A et al (1993). Dopaminergic D2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. J Nucl Med 34:1717-1721.
15. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB (2005). Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 102:12560-12565.
16. Dionisi-Vici C, Hoffmann GF, Leuzzi V, Hoffken H, Brautigam C, Rizzo C et al (2000). Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr 136:560-562.
17. Dura E, Villard L, Roux JC (2008). Expression of methyl CpG binding protein 2 (Mecp2) during the postnatal development of the mouse brainstem. Brain Res 1236:176-184.
18. Espadas I, Darmopil S, Vergano-Vera E, Ortiz O, Oliva I, Vicario-Abejon C et al (2012). L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 48:271-281.
19. Fasano C, Bourque MJ, Lapointe G, Leo D, Thibault D, Haber M et al (2013). Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology 67:432-443.
20. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V et al (2005). Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 14:3565-3577.
21. Fiala JC, Spacek J, Harris KM (2002). Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Rev 39:29-54.
22. FitzGerald PM, Jankovic J, Glaze DG, Schultz R, Percy AK (1990). Extrapyramidal involvement in Rett's syndrome. Neurology 40:293-295.
23. Gamer M, Lemon J, Fellows I, Singh P (2012). irr: Various Coefficients of Interrater Reliability and Agreement. R package version 0.84.
24. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007). Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143-1147.
25. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001). A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27:322-326.
26. Ide S, Itoh M, Goto Y (2005). Defect in normal developmental increase of the brain biogenic amine concentrations in the mecp2-null mouse. Neurosci Lett 386:14-17.
27. Jellinger K, Armstrong D, Zoghbi HY, Percy AK (1988). Neuropathology of Rett syndrome. Acta Neuropathol 76:142-158.
28. Jellinger KA (2003). Rett Syndrome - an update. J Neural Transm 110:681-701.
29. Jenner P (2008). Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64 (Suppl 2): S16-S29.
30. Kao FC, Su SH, Carlson GC, Liao W (2013). MeCP2-mediated alterations of striatal features accompany psychomotor deficits in a mouse model of Rett syndrome. Brain Struct Funct (e-pub ahead of print 12 November 2013).
31. Kishi N, Macklis JD (2004). MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 27:306-321.
32. Kitt CA, Wilcox BJ (1995). Preliminary evidence for neurodegenerative changes in the substantia nigra of Rett syndrome. Neuropediatrics 26:114-118.
33. Lekman A, Witt-Engerstrom I, Gottfries J, Hagberg BA, Percy AK, Svennerholm L (1989). Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr Neurol 5:357-362.
34. Lopez-Erauskin J, Fourcade S, Galino J, Ruiz M, Schluter A, Naudi A et al (2011). Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol 70:84-92.
35. Ludecke B, Dworniczak B, Bartholome K (1995). A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet 95:123-125.
36. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004). Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA 101:6033-6038.
37. Mena MA, Casarejos MJ, Solano RM, de Yebenes JG (2009). Half a century of L-DOPA. Curr Top Med Chem 9:880-893.
38. Molinoff PB, Axelrod J (1971). Biochemistry of catecholamines. Annu Rev Biochem 40:465-500.
39. Neul JL, Zoghbi HY (2004). Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 10:118-128.
40. Nguyen MV, Du F, Felice CA, Shan X, Nigam A, Mandel G et al (2012). MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci 32:10021-10034.
41. Nomura Y, Kimura K, Arai H, Segawa M (1997). Involvement of the autonomic nervous system in the pathophysiology of Rett syndrome. Eur Child Adolesc Psychiatry 6:42-46.
42. Olanow CW, Watts RL, Koller WC (2001). An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 (Suppl 5): S1-S88.
43. Panayotis N, Pratte M, Borges-Correia A, Ghata A, Villard L, Roux JC (2011). Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol Dis 41:385-397.
44. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW (2000). New dopaminergic neurons in Parkinson's disease striatum. Lancet 356:44-45.
45. R Core Team (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, http://www. R-project.org/.
46. Riederer P, Weiser M, Wichart I, Schmidt B, Killian W, Rett A (1986). Preliminary brain autopsy findings in progredient Rett síndrome. Am J Med Genet Suppl 1:305-315.
47. Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL (2008). Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PLoS ONE 3:e1997.
48. Rodriguez A, Ehlenberger DB, Hof PR, Wearne SL (2006). Rayburst sampling, an algorithm for automated three-dimensional shape analysis from laser scanning microscopy images. Nat Protoc 1:2152-2161.
49. Roux JC, Dura E, Moncla A, Mancini J, Villard L (2007). Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 25:1915-1922.
50. Samaco RC, Mandel-Brehm C, Chao HT, Ward CS, Fyffe-Maricich SL, Ren J et al (2009). Loss of MeCP2 in aminergic neurons causes cellautonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci USA 106:21966-21971.
51. Santini E, Alcacer C, Cacciatore S, Heiman M, Hervé D, Greengard P et al (2009). L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108:621-633.
52. Sholl DA (1953). Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87:387-406.
53. Tandé D, Höglinger G, Debeir T, Freundlieb N, Hirsch EC, François C (2006). New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129:1194-1200.
54. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pena F et al (2005). Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25:11521-11530.
55. Wenk GL, Naidu S, Casanova MF, Kitt CA, Moser H (1991). Altered neurochemical markers in Rett's syndrome. Neurology 41:1753-1756.